Persistent low-level viraemia (LLV) during the treatment of antiretroviral therapy (ART) is associated with emergent drug resistance mutation (DRM); however, insight into its driver is limited. The objectives were to study HIV-1 pol sequence evolution in subjects with persistent LLV and evaluate factors associated with sequence changes.
Methods
HIV-1 pol sequences from 54 treatment-naive subjects undergoing first-line lopinavir/ritonavir- or efavirenz-containing ART were obtained at pre-ART and end of LLV. HIV-1 sequence evolution was evaluated using phylogenetic analysis and Hamming distance calculation. DRMs were interpreted based on the International AIDS Society-USA 2011 update.
Results
Subjects with new DRM during LLV had greater HIV-1 evolution across pol from the pre-ART to end of LLV compared with subjects without DRM. Evolution over non-DRM sites was similar between groups. Higher degree of genetic evolution was positively associated with higher HIV-1 RNA levels during LLV, both at DRM and non-DRM sites.
Conclusions
The magnitude of LLV was the primary driver of evolution rate at DRM as well as non-DRM sites. Higher viral load was associated with DRM emergence in these subjects. These findings provide insights that may be applicable to the management of patients with persistent LLV during ART.
References
1.
LapriseC., de PokomandyA., BarilJ.G., DufresneS., TrottierH.Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation.Clin Infect Dis2013; 57: 1489–1496.
2.
CohenC.Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.HIV Clin Trials2009; 10: 116–124.
3.
SungkanuparphS., GrogerR.K., OvertonE.T., FraserV.J., PowderlyW.G.Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.HIV Med2006; 7: 437–441.
4.
SwensonL.C., MinJ.E., WoodsC.K.HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure.AIDS2014; 28: 1125–1134.
5.
Gonzalez-SernaA., MinJ.E., WoodsC.Performance of HIV-1 drug resistance testing at low level viraemia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals.Clin Infect Dis2014; 58: 1165–1173.
6.
TaiwoB., GallienS., AgaE.Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.J Infect Dis2011; 204: 515–520.
7.
LiJ.Z., GallienS., DoT.R., MartinJ.N., DeeksS., KuritzkesD.R.Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.Antimicrob Agents Chemother2012; 56: 5998–6000.
8.
AlemanS., SoderbargK., Visco-ComandiniU., SitbonG., SonnerborgA.Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.AIDS2002; 16: 1039–1044.
9.
KarlssonA.C., YoungerS.R., MartinJ.N.Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia.AIDS2004; 18: 981–989.
10.
DelaugerreC., GallienS., FlandreP.Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.PLoS ONE2012; 7: e36673.
11.
JohnsonV.A., CalvezV., GunthardH.F.2011 Update of the drug resistance mutations in HIV-1.Top Antivir Med2011; 19: 156–164.
12.
HightowerG.K., MayS.J., Pérez-SantiagoJ.HIV-1 clade B pol evolution following primary infection.PLoS ONE2013; 8: e68188.
13.
MollanK., DaarE.S., SaxP.E.HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.J Infect Dis2012; 206: 1920–1930.
14.
NeiM., GojoboriT.Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions.Mol Biol Evol1986; 3: 418–426.
KorberB.HIV signature and sequence variation analysis. In AllenG., RodrigoA.G., LearnG.H. (Editors). Computational analysis of HIV molecular sequences. Dordrecht, Netherlands: Kluwer Academic Publishers2000; 55–72.
18.
GünthardH.F., FrostS.D., Leigh-BrownA.J.Evolution of envelope sequence of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy.J Virol1999; 73: 9404–9412.
